Tamoxifen

ID: tamoxifen

Aliases: tamoxifen citrate, Nolvadex, Soltamox

Type: compound

Route/form: oral

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, human_trial, label, systematic_review

Linked sources: 5

Broad outcomes: Hormones / fertility / sexual health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• estrogen receptor modulator
• ER antagonist in breast tissue
• partial ER agonist in bone and endometrium

Optimization domains

• SERM
• breast cancer
• gynecomastia
• endocrine
• PCT discussions

Research basis

• Optimization angle: breast-tissue ER antagonism is why tamoxifen appears in gynecomastia mitigation and PCT discussions rather than as a performance enhancer.
• Human label, gynecomastia reviews, and male antiestrogen physiology data provide mechanism anchors for estrogen-receptor modulation in breast/endocrine contexts.
• It can be rational as an estrogenic-side-effect tool, but that is different from fixing androgen suppression or preserving fertility.

Limits, risks, and missing evidence

• VTE, ocular effects, hepatic considerations, CYP2D6 interactions, mood/sexual side effects, and endometrial risk in female label contexts make casual use inappropriate.
• Male gynecomastia/PCT use is off-label and should not be treated like an automatic antidote to androgen suppression.
• Older male infertility antiestrogen data are mixed, so fertility claims need endpoint-specific evidence rather than generic SERM logic.

Risk flags

• prescription only
• thrombotic risk
• off label male context
• drug interactions

Linked papers, labels, and reviews

1. DailyMed label: tamoxifen citrate tablet
   label / dailymed_tamoxifen_label
   Approved SERM label covering breast cancer treatment and risk-reduction contexts.
2. Randomized trial of tamoxifen therapy vs prophylaxis in bicalutamide-induced gynecomastia
   human_rct / pubmed_tamoxifen_gynecomastia_2012
   Male gynecomastia context; not a general PCT validation source.
3. Gynecomastia: a systematic review of pharmacological treatments
   systematic_review / pubmed_gynecomastia_pharm_review_2022
   Reviews SERM, aromatase inhibitor, and androgen pharmacologic approaches for gynecomastia.
4. Antiestrogenic properties of raloxifene
   human_trial / pubmed_raloxifene_tamoxifen_male_antiestr_1995
   Healthy-male volunteer study comparing raloxifene/tamoxifen endocrine responses to estrogen challenge; useful SERM mechanism anchor.
5. Effectiveness of antiestrogens in infertile men
   human_trial / pubmed_antiestrogens_infertile_men_1993
   Older male infertility antiestrogen follow-up; useful negative/mixed endpoint context for clomiphene/tamoxifen fertility claims.